Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 13, 2012

 

 

BG Medicine, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

001-33827

(Commission File Number)

 

Delaware   04-3506204

(State or Other Jurisdiction

of Incorporation)

  

(IRS Employer

Identification No.)

610 Lincoln Street North, Waltham, Massachusetts   02451
(Address of Principal Executive Offices)   (Zip Code)

(781) 890-1199

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item. 7.01 Regulation FD Disclosure.

On February 13, 2012, members of senior management of BG Medicine, Inc. (the “Company”) are delivering the attached investor presentation to attendees of the Company’s Investor and Analyst Briefing and webcast. The presentation is attached as exhibit 99.1 to this Current Report on Form 8-K. Pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”), exhibit 99.1 and the information set forth therein and herein are deemed to be furnished to the Commission and shall not be deemed to be filed with or incorporated by reference into any filing with the Commission.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1    Investor and Analyst Briefing Presentation dated February 13, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     BG MEDICINE, INC.

Date: February 13, 2012

     

/s/ Michael W. Rogers

     Michael W. Rogers
     Executive Vice President & Chief Financial Officer